Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study

Jordana E. Hoppe, Mark Chilvers, Félix Ratjen, John McNamara, Caroline A. Owen, Simon Tian, Rachel Zahigian, Alexandra G. Cornell, Susanna A. McColley